Pae Chi-Un, Marks David M, Han Changsu, Masand Prakash S, Patkar Ashwin A
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea.
Int Clin Psychopharmacol. 2009 Jan;24(1):29-33. doi: 10.1097/YIC.0b013e32831feea9.
This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dosed pregabalin for 6 weeks. All patients were assessed with the Short PTSD Rating Interview, Montgomery-Asberg Depression Rating Scale, Patient Global Impression-severity, Visual Analog Scale-pain, and Sheehan Disability Scale at baseline and weeks 2, 4, and 6. Significant reductions were observed in all effectiveness measures from week 4 to the end of the study. In particular, the numerical improvement of the Visual Analog Scale-pain score was most robust (-53.4%, P=0.007). Pregabalin augmentation was effective and well tolerated during the study. Our findings warrant adequately powered, placebo-controlled clinical trials to confirm the usefulness of pregabalin augmentation of antidepressants in patients with PTSD.
本研究评估了普瑞巴林增强抗抑郁治疗对创伤后应激障碍（PTSD）患者的疗效。9例符合《精神疾病诊断与统计手册》第四版PTSD标准且抗抑郁药剂量稳定的患者，接受了灵活剂量的普瑞巴林开放标签治疗，为期6周。在基线以及第2、4和6周时，所有患者均接受了创伤后应激障碍简短评定访谈、蒙哥马利-阿斯伯格抑郁评定量表、患者整体印象-严重程度、视觉模拟评分-疼痛和希恩残疾量表评估。从第4周直至研究结束，所有疗效指标均有显著下降。特别是，视觉模拟评分-疼痛得分的数值改善最为显著（-53.4%，P=0.007）。在研究期间，普瑞巴林增强治疗有效且耐受性良好。我们的研究结果需要开展有足够效力的、安慰剂对照的临床试验，以证实普瑞巴林增强抗抑郁药对PTSD患者的有效性。
